We previously reported that some ATP competitive protein kinase C (PKC) inhibitors are either competitive or uncompetitive inhibitors with respect to substrate peptides. In this report, we demonstrate how the interactions between PKC and inhibitors change PKC activation kinetics. A substrate competitive inhibitor, bisindolylmaleimide I, targets activated PKC and stabilizes PKC in the activated conformation. This leads to transient activation and prolonged deactivation of PKC in the presence of bisindolylmaleimide I. In contrast, an uncompetitive substrate inhibitor, bisindolylmaleimide IV, targets quiescent PKC and stabilizes PKC in the quiescent conformation, which generates slower activation and suppressed translocation upon activation of...
Protein kinases are one of the largest known families of enzyme characterized by having a well conse...
LY333531, BIM-1, BIM-2, BIM-3, and BIM-8 are bisindolyl maleimide-based, nanomolar protein kinase C ...
Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors...
We previously reported that some ATP competitive protein kinase C (PKC) inhibitors are either compet...
In view of the critical role that the Ca2+- and phospholipid-dependent enzyme protein kinase C (PKC)...
ATP-competitive inhibitors are currently the largest class of clinically approved drugs for protein ...
Kinases present an attractive target for drug development, since they are involved in vital cellular...
Kinase inhibitors are increasingly important in drug development. Because the majority of current in...
As the key mediators of eukaryotic signal transduction, the protein kinases often cause disease, and...
SummaryMost potent protein kinase inhibitors act by competing with ATP to block the phosphotransfera...
Although protein kinase inhibitors present excellent pharmaceutical opportunities, lack of selectivi...
Protein kinases are now recognised as an important class of drug targets. Whilst many protein kinase...
<p>Schematic diagrams (top), cartoons for relevant states of PKC (middle) and time course of PKC act...
LY333531, BIM-1, BIM-2, BIM-3, and BIM-8 are bisindolyl maleimide-based, nanomolar protein kinase C ...
Protein kinases play a pivotal role in cell signaling, and dysregulation of many kinases has been li...
Protein kinases are one of the largest known families of enzyme characterized by having a well conse...
LY333531, BIM-1, BIM-2, BIM-3, and BIM-8 are bisindolyl maleimide-based, nanomolar protein kinase C ...
Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors...
We previously reported that some ATP competitive protein kinase C (PKC) inhibitors are either compet...
In view of the critical role that the Ca2+- and phospholipid-dependent enzyme protein kinase C (PKC)...
ATP-competitive inhibitors are currently the largest class of clinically approved drugs for protein ...
Kinases present an attractive target for drug development, since they are involved in vital cellular...
Kinase inhibitors are increasingly important in drug development. Because the majority of current in...
As the key mediators of eukaryotic signal transduction, the protein kinases often cause disease, and...
SummaryMost potent protein kinase inhibitors act by competing with ATP to block the phosphotransfera...
Although protein kinase inhibitors present excellent pharmaceutical opportunities, lack of selectivi...
Protein kinases are now recognised as an important class of drug targets. Whilst many protein kinase...
<p>Schematic diagrams (top), cartoons for relevant states of PKC (middle) and time course of PKC act...
LY333531, BIM-1, BIM-2, BIM-3, and BIM-8 are bisindolyl maleimide-based, nanomolar protein kinase C ...
Protein kinases play a pivotal role in cell signaling, and dysregulation of many kinases has been li...
Protein kinases are one of the largest known families of enzyme characterized by having a well conse...
LY333531, BIM-1, BIM-2, BIM-3, and BIM-8 are bisindolyl maleimide-based, nanomolar protein kinase C ...
Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors...